Publicacións nas que colabora con Manuel Barreiro de Acosta (16)

2024

  1. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  2. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  3. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

2023

  1. Enfermedad inflamatoria intestinal

    Microbiota, probióticos y prebióticos: evidencia científica (Ergon), pp. 389-392

  2. Is Occupation a Risk Factor for Developing Inflammatory Bowel Disease? A Case–Control Study

    Crohn's and Colitis 360, Vol. 5, Núm. 4

  3. Managing ulcerative colitis after surgery

    Frontiers in Medicine

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Radon exposure and inflammatory bowel disease in a radon prone area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 405-409

  3. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 1, pp. 10-15

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Role of quality of life as endpoint for inflammatory bowel disease treatment

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 13

2020

  1. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy

    Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 1, pp. 135-142

  2. Pouchitis: Treatment dilemmas at different stages of the disease

    United European Gastroenterology Journal, Vol. 8, Núm. 3, pp. 256-262

  3. Should We Investigate Respiratory Diseases in Inflammatory Bowel Disease Patients?

    Archivos de Bronconeumologia

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12